Price$7.08+0.13 (+1.80%)
01:30 PM07:45 PM
News · 26 weeks28-86%
2025-12-142026-06-07
Mix1190d
- SEC Filings5(45%)
- Other4(36%)
- Earnings2(18%)
Latest news
25 items- PRPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on June 1, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 7,000 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, June 1, 2026, a
- SECSEC Form 10-Q filed by Puma Biotechnology Inc10-Q - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
- SECPuma Biotechnology Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
- PRPuma Biotechnology Reports First Quarter 2026 Financial ResultsRaising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2026. Unless otherwise stated, all comparisons are for the first quarter 2026 compared to the first quarter 2025. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the first quarter of 2026 was $42.0 million, compared to product revenue, net of $43.1 million in the first quarter of 2025. Based on accounting principles generally accepted in the United States (GAAP), Puma reported a net loss o
- PRPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on May 5, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 59,750 shares of Puma common stock to six new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, May 1, 2026, an
- SECSEC Form DEFA14A filed by Puma Biotechnology IncDEFA14A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
- SECSEC Form DEF 14A filed by Puma Biotechnology IncDEF 14A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
- PRPuma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial ResultsPuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 7, 2026, following the release of its first quarter 2026 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approximately one hour afte
- SECSEC Form PRE 14A filed by Puma Biotechnology IncPRE 14A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
- PRPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on April 1, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 31,625 shares of Puma common stock to five new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, April 1, 202
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Puma Biotechnology IncSCHEDULE 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
- SECSEC Form 10-K filed by Puma Biotechnology Inc10-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
- SECPuma Biotechnology Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
- PRPuma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial ResultsPuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2025 compared to the fourth quarter and full year 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the fourth quarter of 2025 was $59.9 million, compared to $54.4 million in the fourth quarter of 2024. Product revenue, net for the full year 2025 was $204.1 million, compared to $195.2 million in 2024. Based on accounting principles generally accepted in the United State
- PRPuma Biotechnology to Present at TD Cowen's 46th Annual Health Care ConferencePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:30 p.m. ET on Monday, March 2, at the TD Cowen 46th Annual Health Care Conference. The conference will be held March 2–4, 2026 at the Boston Marriott Copley Place in Boston. A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days. About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutic
- INSIDERPresident and CEO Auerbach Alan H was granted 159,778 shares, increasing direct ownership by 2% to 7,305,729 units (SEC Form 4)4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
- INSIDEROfficer Hunt Douglas M was granted 49,394 shares, increasing direct ownership by 32% to 205,301 units (SEC Form 4)4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
- INSIDERChief Financial Officer Nougues Maximo F was granted 46,739 shares, increasing direct ownership by 24% to 240,023 units (SEC Form 4)4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
- PRPuma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial ResultsPuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, February 26, 2026, following the release of its fourth quarter and full year 2025 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available shortl
- PRPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on February 3, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 14,750 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, February 1
- INSIDERPresident and CEO Auerbach Alan H sold $204,878 worth of shares (34,950 units at $5.86), decreasing direct ownership by 0.49% to 7,145,951 units (SEC Form 4)4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
- INSIDEROfficer Hunt Douglas M sold $52,696 worth of shares (8,987 units at $5.86), decreasing direct ownership by 5% to 155,907 units (SEC Form 4)4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
- INSIDERChief Financial Officer Nougues Maximo F sold $64,187 worth of shares (10,945 units at $5.86), decreasing direct ownership by 5% to 193,284 units (SEC Form 4)4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
- PRPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on January 6, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 10,500 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, January 1
- SECSEC Form 144 filed by Puma Biotechnology Inc144 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
PBYI FAQ
6 questionsWhat does Puma Biotechnology Inc do?
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a...Where does PBYI stock trade?
Puma Biotechnology Inc (PBYI) is listed on NASDAQ.What sector and industry is PBYI in?
Puma Biotechnology Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PBYI?
Puma Biotechnology Inc has had 4 recent analyst actions on file. The most recent action was from Citigroup: Buy with a $1100.00 price target on 2021-09-28. Recent price targets range from $600.00 to $1100.00.What companies are similar to PBYI?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PBYI side-by-side with any of them on Quantisnow.How can I track PBYI on Quantisnow?
Quantisnow aggregates Puma Biotechnology Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PBYI to receive live email and push alerts on every new disclosure.